1. Introduction {#s0005}
===============

With a rapid rise in number of type 2 diabetes (T2D) patients, diabetic nephropathy has become the leading cause of chronic kidney disease (CKD). In recent decades, CKD has been an important public health problem in both developed and developing countries ([@bb0120], [@bb0180]). The evaluation of diabetic nephropathy depends on assessment of two markers, albumin excretion rate and glomerular filtration rate (GFR) ([@bb0100]). It is generally believed that microalbuminuria is an early clinical manifestation of diabetic nephropathy, and that decreased GFR occurs secondarily, mainly in individuals with longstanding diabetes ([@bb0160]). Randomized controlled trials (RCTs) have also shown that intensive diabetes treatment was associated with better renal outcomes, including lowering risk of albuminuria and increasing estimated GFR (eGFR) ([@bb0025], [@bb0050], [@bb0020]), suggesting a possible causal link between diabetes and renal outcomes. However, because conventional epidemiological studies are subject to a variety of bias such as confounding or reverse causation, and the RCTs are largely limited by short-term intervention, other novel approaches are needed to investigate the causal relation between T2D and renal dysfunction.

Recently, the Mendelian Randomization (MR) approach has been widely used for assessing causality in population studies ([@bb0090], [@bb0060]). Because the genetic alleles are allocated randomly during gamete formation and are inherited independent of potential confounding factors and represented as a life-long exposure, using the genetic variants as the instrumental variable (IV) have become a widely-used approach for causal inference ([@bb0115]).

In the present study, we performed a MR analysis to explore the causal relation between T2D and decreased eGFR and increased uACR, in a large community-based sample of Chinese participants. In order to reduce the statistical errors with multi-testing, we created a T2D genetic risk score (GRS) by using 34 T2D associated common variants that were identified in East Asians and represented the comprehensive genetic susceptibility of T2D, to be used as the IV ([@bb0145], [@bb0125]). In addition, we also explored the genetic variations according to their roles in insulin secretion and insulin resistance.

2. Material and Methods {#s0010}
=======================

2.1. Study Participants {#s0015}
-----------------------

The present analysis was one part of an ongoing study of the Risk Evaluation of cAncers in Chinese diabeTic Individuals: a lONgitudinal (REACTION) study, which is a large, nationwide, prospective study involving 259,657 community-dwelling adults, aged 40 years or older. Details of the study rationale and profile have been published elsewhere ([@bb0140], [@bb0015]). The study participants were recruited from two nearby communities at Baoshan district in Shanghai during 2011 and 2013. A standard questionnaire was used to collect information about lifestyle factors, disease and medical history. Anthropometric measurements, 75-g oral glucose tolerance tests (OGTT) were performed to determine the glucose metabolism status; blood and urine samples were collected for the measurements of interests.

11,935 participants (average age 63.5 years and 35.6% men) were recruited, in which genotype information was available in 11,837 ones (99.2%). Individuals with missing information on eGFR or urinary albumin-to-creatinine ratio (uACR) (*n* = 95) were excluded. We further excluded the participants who were missing more than two variants (*n* = 240). Thus, a total of 11,502 participants were included in the final analysis. The Institutional Review Board of Rui-Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine approved the study protocol. Written informed consent was obtained from each participant.

2.2. Anthropometric Information and Biochemical Measurements {#s0020}
------------------------------------------------------------

A standard questionnaire was used to collect the social demographic information, the history of chronic diseases and medications, and lifestyle factors such as smoking and drinking status and physical activity. The current smoking or drinking was defined as \'yes\' if the subject smoked at least one cigarette or consumed alcohol at least once a week in the past 6 month. Physical activity at leisure time was estimated by using the short form of the International Physical Activity Questionnaire (IPAQ) ([@bb0075]). Trained investigators measured body height and body weight. Body mass index (BMI) was calculated as weight in kilograms divided by height squared in meters (kg/m^2^). Systolic and diastolic blood pressures (SBP and DBP) were measured in triplicate on the same day after at least ten-min rest by using an automated electronic device (OMRON Model HEM-752 FUZZY, Omron Company, Dalian, China), and the average value of the three measurements was used for analysis. The SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg, or those who were taking anti-hypertension medications were diagnosed as hypertension.

Fasting and 2-hour post-loading plasma glucose (FPG and 2 h PG) were measured by using hexokinase method on a clinical chemistry diagnostic system (C16000, Abbott Laboratories, Otawara-shi, Japan). Serum fasting insulin was measured by using the immunoassay diagnostic system (I2000, Abbott Laboratories, Dallas, USA). The homeostasis model assessment of insulin resistance index (HOMA-IR) was calculated as fasting insulin (μIU/ml) × fasting glucose (mmol/l) / 22.5 ([@bb0135]). The homeostasis model assessment of β cell function or insulin secretion (HOMA-β) was calculated by using the formula: HOMA-β = \[20 ∗ fasting insulin (uIU/ml)\] / \[fasting glucose (mmol/l) − 3.5\] ([@bb0030]). According to the 1999 World Health Organization diagnostic criteria ([@bb0010]), type 2 diabetes was defined as FPG ≥ 7.0 mmol/l and/or 2 h-OGTT PG ≥ 11.1 mmol/l and/or treatment with anti-diabetic medication and/or previously diagnosed diabetes by physicians. Fasting serum total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-cholesterol) and low-density lipoprotein cholesterol (LDL-cholesterol) were measured by using the clinical chemistry diagnostic system (C16000, Abbott Laboratories, Otawara-shi, Japan).

2.3. Assessment of Decreased eGFR and Increased uACR {#s0025}
----------------------------------------------------

The abbreviated Modification of Diet in Renal Disease (MDRD) formula recalibrated for Chinese was used to estimate GFR ([@bb0130]). The formula was: eGFR = 186 × \[serum creatinine × 0.011\]^− 1.154^ × \[age\]^− 0.203^ × \[0.742 if female\] × 1.233, where 1.233 was the adjusting coefficient for Chinese and eGFR was expressed in ml/min/1.73 m^2^. Decreased eGFR was defined as eGFR \< 90 ml/min/1.73 m^2^ ([@bb0085]), with mildly decreased eGFR defined as eGFR of 60--89 ml/min/1.73 m^2^, and moderately to severely decreased eGFR defined as eGFR \< 60 ml/min/1.73 m^2^.

Urinary albumin and creatinine concentrations were determined in the first-void sterile urine samples in the early morning by rate nephelometry (Beckman Coulter, Fullerton, CA) and alkaline nitroxanthic acid method (Beckman LX/20, Brea, CA), respectively. The increased uACR was defined as a uACR ≥ 30 mg/g, with micro-albuminuria defined as a uACR of 30--299 mg/g, and macro-albuminuria as a uACR ≥ 300 mg/g ([@bb0160]).

2.4. Selection of Genetic Loci, Genotyping, and Genetic Risk Score Construction {#s0030}
-------------------------------------------------------------------------------

On considering the population specificity of genetic background, the selected variants or single nucleotide polymorphisms (SNPs) were either discovered in Europeans and replicated in East Asians ([@bb0040], [@bb0110]) or those identified and validated in meta-analysis including GWASs from East Asians ([@bb0035]), including: *PROX1* rs213985913, *BCL11* rs60357484, *GCKR* rs27518370, *IRS1* rs226229029, *IGF2BP2* rs185793899, *PPARG* rs12351626, *PSMD6* rs64062621, *UBE2E2* rs23294959, *MAEA* rs1316113, *CDKAL1* rs20685255, *ZFAND3* rs38139068, *DGKB* rs15024684, *GCC1*/*PAX4* rs127524904, *JAZF1* rs28140937, *SLC30A8* rs117172544, *TP53INP1* rs94948283, *CDKN2A*/*B* rs22134095, *GLIS3* rs4287466, *PTPRD* rs8879118, *CDC123*/*CAMK1D* rs12272998, *CDC123*/*CAMK1D* rs12286011, *HHEX*/*IDE* rs92703125, *TCF7L2* rs112998590, *CENTD2* rs72722053, *KCNQ1* rs2670241, *KCNQ1* rs2818521, *KCNJ11* rs17387083, *SPRY2* rs80143021, *C2CD4A*/*C2CD4B* rs62104190, *FTO* rs53779455, *TCF2* (*HNF1B*) rs37738049, *SRR* rs2312964, *PEPD* rs33402102 and *FITM2*/*R3HT2DL*/*HNF4A* rs44318326 (Supplementary Table 1). They all reached a genome-wide significance level (*P* \< 5 × 10^− 8^) and no linkage disequilibrium relationship existed among the above loci (*r*^*2*^ = 0.000, except it was 0.055 between rs10906115 and rs12779790 in *CDC123*/*CAMK1D*) according to the data of East Asian ancestries in the International HapMap release 21. For the GRS construction, we assumed the additive genetic model ([@bb0145]) for each variant, applying a linear weighing of 0, 1, and 2 to genotypes containing 0, 1, or 2 risk alleles, respectively. The weighted GRS was calculated by weighting each risk allele with the effect size (the natural log of the odds ratios \[ORs\]) for risk of T2D summarized in the literature ([@bb0040]). We excluded the participants who were missing more than two variants (*n* = 240). Thus, a total of 11,502 participants were included in the final analysis. With those who were missing one or two variants, we assigned them the average GRS. Using these 34 variants, we created a GRS ranging from 21.02--49.39 (weighted) and 22.00--48.42 (un-weighted). All the results in the present study were by using the weighted GRS, and the un-weighted GRS was used in the sensitivity analysis.

Additionally, we grouped the genetic variations according to their associations with insulin secretion or insulin resistance (Supplementary Table 2). Among the 34 variants, 16 were found significantly associated with Log-HOMA-β and 6 were associated with Log-HOMA-IR. Using the 16 insulin secretion related variants, we created a weighted IS-GRS ranging from 6.48 to 25.60 based on weighting each allele with the effect size (β) on association with Log-HOMA-β; and using the 6 insulin resistance related variants to create a weighted IR-GRS ranging from 3.20 to 12.00 based on weighting each allele with the effect size (β) on association with Log-HOMA-IR.

Blood white cells were collected for DNA extractions by using commercial blood genomic DNA extraction kit (OSR-M102-T1, TIANGEN BIOTECH CO, LTD, Beijing, China) on an automated nucleic acid extraction instrument (OSE-M48, TIANGEN BIOTECH CO, LTD, Beijing, China) according to the manufacturer\'s standard protocol. Specific assays were designed using the MassARRAY Assay Design software package (v3.1) (<https://www.agenacx.com/Home>). Mass determination was carried out with the MALDI-TOF mass spectrometer and data acquisition was used MassARRAY Type 4.0 software (SEQUENOM, CapitalBio Corporation, Beijing, China). The minimum call rate was 98.7%. The concordance rate is more than 99% based on 100 duplicates genotyping. Most of the SNPs were in Hardy--Weinberg equilibrium (HWE).

2.5. Statistical Analysis {#s0035}
-------------------------

SAS version 9.3 (SAS Institute, Cary, NC) was used for database management and statistical analysis. Serum TG, HOMA-IR and HOMA-β were normalized by logarithmic transformation because of skewed distributions. Continuous variables were given as age-, sex- and BMI-adjusted means ± standard error \[SE\]. Categorical variables were shown in proportions. Linear regression analysis and Cochran--Armitage trend chi-square test were used to test for trends across the T2D_GRS quartiles for continuous variables and categorical variables. Multivariable-adjusted linear regression models were fitted to evaluate the association of T2D-, IR- and IS-GRS with Log-eGFR and Log-uACR, respectively. Multivariable logistic regression models were used to assess the associations between the GRSs and decreased eGFR and increased uACR. The adjustment included age (years), sex, BMI (kg/m^2^), current smoking (yes or no), current drinking (yes or no), physical activity (mild, moderate or vigorous), hypertension (yes or no), total cholesterol (mmol/l), HDL-cholesterol (mmol/l), LDL-cholesterol (mmol/l) and triglycerides (mmol/l). Multinomial logistic regression models were fitted to assess the associations of T2D-GRS with mildly and moderately to severely decreased eGFR, as well as micro- and macro-albuminuria. Statistical significance was set to a two-sided *P* value of less than 0.05.

In the MR analysis, we used the IV estimators to measure the strength of the causal relationship between T2D and decreased eGFR and increased uACR. The IV estimate of causal OR was derived by using the Wald-type estimator ([@bb0070]) and then exponentiating to express as an OR. The computational formula was OR~*IV*~ = exp (Ln (OR ~GRS − outcome~) / Ln (OR ~GRS − T2D~)), in which Ln (OR ~GRS − outcome~) was *β*~*GRS* - *outcome*~ and Ln (OR ~GRS − T2D~) was *β*~*GRS* - *T*2*D*~. The SE for the IV estimators was estimated using the delta method.$$\mathit{SE}_{\mathit{IV}} = \mathit{abs}\left( \beta_{\mathit{IV}} \right)\sqrt{\left( \frac{\mathit{SE}_{{GRS} - T2D}}{\beta_{{GRS} - T2D}} \right)^{2} + \left( \frac{\mathit{SE}_{{GRS} - \text{outcome}}}{\beta_{{GRS} - \text{outcome}}} \right)^{2}\mspace{9mu}}$$

Based on these estimates, we appeal to standard-normal asymptotics, with the resulting Wald test statistic and 95% confidence intervals (CIs) given as$$Z_{\mathit{IV}} = \frac{\beta_{\mathit{IV}}}{SE_{\mathit{IV}}}\quad\text{OR}_{\mathit{IV}} = \exp\left( \beta_{\mathit{IV}} \right)\quad 95\%\mspace{9mu}{CI}_{\mathit{IV}} = \exp\left( {\beta_{\mathit{IV}} \pm 1.96\mspace{9mu} SE_{\mathit{IV}}} \right)$$

The *P-*value for the *H*~0~: β~*IV*~ = 0 was derived from the standard normal distribution. For the ORs associated with dichotomous traits (decreased eGFR or increased uACR), the 95% CI estimates were back-transformed through the exponentiation.

The IV estimates were adjusted for age (years), sex, BMI (kg/m^2^), current smoking (yes or no), current drinking (yes or no), physical activity (mild, moderate or vigorous), hypertension (yes or no), total cholesterol (mmol/l), HDL-cholesterol (mmol/l), LDL-cholesterol (mmol/l) and triglycerides (mmol/l).

3. Results {#s0040}
==========

3.1. Characteristics of Study Participants {#s0045}
------------------------------------------

The characteristics of individual variants included in the T2D_GRS and their associations with T2D were shown in Supplementary Table 1. Mean value of the weighted T2D_GRS was 34.53 with a standard deviation (SD) of 3.90 (Supplementary Figure 1). Sociodemographic and clinical characteristics of participants according to quartiles of weighted T2D_GRS were displayed in [Table 1](#t0005){ref-type="table"}. Among the 11,502 participants, 4101 (35.7%) were men and 2869 (24.9%) were T2D patients. The average age was 63.3 years (SD, 13.5). The levels of serum creatinine and uACR were increasing across T2D_GRS quartiles, while the eGFR levels were decreasing. The prevalence of decreased eGFR was increasing across the T2D_GRS quartiles (*P* for trend = 0.02).

3.2. Associations of T2D-GRS with Decreased eGFR and Increased uACR {#s0050}
-------------------------------------------------------------------

As shown in [Table 2](#t0010){ref-type="table"}, per SD (3.90 points) increase in T2D_GRS was associated with 12% increased risk of decreased eGFR after adjustment for age, sex and BMI (95% CI: 1.04, 1.20, *P* = 0.001). Further adjustment for current smoking and current drinking, physical activity, hypertension and serum lipids did not appreciably change the results (OR = 1.12, 95% CI: 1.04, 1.20, *P* = 0.002). The categorical analysis showed similar results. Compared with the lowest quartile of T2D_GRS, the second, third and highest quartiles were associated with 15%, 19% and 34% increased risk of decreased eGFR, respectively, after adjustment for age, sex, BMI and other covariates (*P* for trend = 0.005). We did not find positive results between T2D_GRS and increased uACR after adjusted for age, sex, BMI and other covariates. The associations of each SNP with decreased eGFR and increased uACR were shown in Supplementary Table 3.

3.3. Associations of T2D with Decreased eGFR and Increased uACR: The MR Analysis {#s0055}
--------------------------------------------------------------------------------

[Fig. 1](#f0005){ref-type="fig"} Panel A shows the comparison of the observed and the IV causal estimated association of T2D with decreased eGFR and increased uACR. T2D was significantly associated with decreased eGFR OR = 1.18 (95% CI: 1.01, 1.38), after adjustment for age (years), sex, BMI (kg/m^2^), current smoking (yes or no), current drinking (yes or no), physical activity (mild, moderate or vigorous), hypertension (yes or no), total cholesterol (mmol/l), HDL-cholesterol (mmol/l), LDL-cholesterol (mmol/l) and triglycerides (mmol/l). In the MR analysis, we found a significant causal relationship between genetically determined T2D and decreased eGFR, with the OR of 1.47 (95% CI, 1.15, 1.88, *P* = 0.0003).

Panel B shows the comparison of the observed and the IV causal estimated association of T2D with increased uACR. The observational analysis showed that T2D was significantly associated with increased uACR, OR = 2.15 (95% CI: 1.88, 2.45) after same adjustments as Panel A. While the MR analysis did not show a significant causal association, with the causal OR of genetically determined T2D for increased uACR, OR = 1.17 (95% CI: 0.94, 1.45).

We also showed the IV estimated results for associations of each individual SNP with decreased eGFR and increased uACR in Supplementary Table 4. The results were similar with the association study in Supplementary Table 3.

3.4. Association of Function-specific GRS with Decreased eGFR and Increased uACR {#s0060}
--------------------------------------------------------------------------------

[Fig. 2](#f0010){ref-type="fig"} shows that per SD (2.52 points) increase in IS_GRS was significantly associated with decreased eGFR, OR = 1.11 (95% CI: 1.04, 1.19, *P* = 0.004) and increased uACR, OR = 1.07 (95% CI: 1.002, 1.13, *P* = 0.04), after adjustment of age (years), sex, BMI (kg/m^2^), current smoking (yes or no), current drinking (yes or no), physical activity (mild, moderate or vigorous), hypertension (yes or no), total cholesterol (mmol/l), HDL-cholesterol (mmol/l), LDL-cholesterol (mmol/l) and triglycerides (mmol/l). Similarly, we found a significant association between IR_GRS with decreased eGFR (OR = 1.09, 95% CI: 1.01, 1.17, *P* = 0.02); while no significant association was found with increased uACR (*P* = 0.95). The IS_GRS was associated with Log-eGFR and Log-uACR (both *P* = 0.04). However, the IR_GRS was only associated with Log-eGFR (*P* = 0.007), but not Log-uACR (*P* = 0.23, [Fig. 3](#f0015){ref-type="fig"}).

When classified decreased eGFR as mildly decreased and moderately to severely decreased eGFR, we found that the T2D_GRS, IS_GRS and IR_GRS were significantly related to mildly decreased eGFR (all *P* ≤ 0.03), but not moderately to severely decreased eGFR (Supplementary Table 5). When classified increased uACR into micro- and macro-albuminuria, we found that both T2D_GRS and IS_GRS was significantly associated with macro-albuminuria (*P* ≤ 0.02), but not micro-albuminuria. We did not find any positive relationship of IR_GRS with micro-albuminuria or with macro-albuminuria (Supplementary Table 5).

3.5. Sensitivity Analysis {#s0065}
-------------------------

In agreement with the conjecture, we observed a consistent and significant association between genetically determined T2D and decreased eGFR with an OR of 1.41 (95% CI: 1.12, 1.77, *P* = 0.0006) using the un-weighted T2D-GRS as the IV, as shown in [Fig. 4](#f0020){ref-type="fig"}. When using the un-weighted T2D_GRS as the IV, we found that genetically determined T2D was causally associated with increased uACR (OR = 1.24, 95% CI: 1.02, 1.53, *P* = 0.02), though we did not find a causal association using the weighted T2D_GRS as the IV. We excluded the 9 SNPs that are not in HWE (Supplementary Table 1, rs1801282, rs831571, rs6467136, rs864745, rs13266634, rs89654, rs17584499, rs111187 and rs1552224) and created a new T2D_GRS/~25\ SNP~ with a mean of 26.10 (SD, 3.52). In the MR analysis, after adjustment of age, sex, BMI, current smoking, current drinking, physical activity, hypertension, total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides, the IV estimate for causal relationship between T2D and decreased eGFR was, OR = 1.42 (95% CI: 1.13--1.79, *P* = 0.0005) ([Fig. 4](#f0020){ref-type="fig"} and Supplementary 2 Panel A).

The T2D_GRS was found to relate to BMI and SBP, in addition to FPG, OGTT-2 h PG, HOMA-IR and HOMA-β (Supplemental Table 6). To lessen the potential influence of pleiotropic effects of the IV, we performed sensitivity analysis by excluding the 16 SNPs linking to BMI, SBP, DBP, TC and TG (Supplemental Table 7, rs5215, rs4402960, rs1111875, rs243021, rs231362, rs10906115, rs3786897, rs9356744, rs17817449, rs6017317, rs17584499, rs2191349, rs1552224, rs7612463, rs13266634 and rs780094), the T2D_GRS composing the SNPs only associated with T2D was associated with decreased eGFR (Supplementary Figure 3, Panel A). The instrumental variable estimate for causal relationship of T2D and decreased eGFR was: OR = 1.38 (95% CI: 1.02, 1.85, *P* = 0.02) ([Fig. 4](#f0020){ref-type="fig"} and Supplementary 3).

4. Conclusions {#s0070}
==============

In the present investigation including 11,502 community dwelling Chinese adults, we found that T2D_GRS composing of 34 T2D common variants discovered in East Asians was significantly associated with decreased eGFR. To the best of our knowledge, the results for the first time provided novel evidence for a causal relationship between genetically determined T2D and decreased kidney function by using MR.

The MR analysis is a recent improvement in genetic epidemiology ([@bb0090], [@bb0060], [@bb0055]). The independent distribution of alleles/genotypes means that the association of a disease with a genetic variation would not be affected by confounders ([@bb0150]). Moreover, because the random assignment of alleles/genotype transferred from parent to offspring occurs at the time of gamete formation, the association between a genetic variation and a disease is free of reverse causation. Besides, MR study is linked to a natural RCT according to the methodology and has particular superiority in assessing the effects of long-term or lifetime exposures ([@bb0150]). Previous MR studies have provided significant evidence to support causal links between biomarkers, traits and cardiovascular diseases ([@bb0045], [@bb0095], [@bb0155]). Our results were consistent with the latest two MR studies which have provided a causal relationship between diabetes and coronary artery disease using diabetes GRS as the IV ([@bb0165], [@bb0005]). Our study, for the first time, provided potential causal evidence between genetically determined T2D and mild renal sufficiency assessed by decreased eGFR using the MR approach.

Earlier stages of renal insufficiency can be detected through serum creatinine and eGFR ([@bb0105]). Individuals with T2D and reduced eGFR have been shown to be at high risk of cardiovascular events, independent of albuminuria and metabolic control ([@bb0170]). Very recently, one study reported that serum urate was causally associated with improved renal function using GRS of uric acid transporters as the IV, implying the mechanism of the potential renal function protection mediated by xanthine oxidase inhibitors ([@bb0080]). In the present investigation, we found that T2D_GRS was significantly associated with decreased eGFR, especially mildly decreased eGFR. Intriguingly, consistent results were obtained when restricting the MR analysis to genetic variations related to decreased insulin secretion and insulin resistance, suggesting that dysfunction in both insulin secretion and insulin sensitivity may causally affect renal insufficiency. Though further replications in other populations are needed, our findings suggest that that long-term treatment with T2D may be beneficial for prevention of diabetic renal impairment.

Measurement of urinary albumin excretion can identify patients with kidney damage ([@bb0105]). Microalbuminuria is now considered as a marker for early diabetic nephropathy ([@bb0175]) and an independent predictor for cardiovascular disease and mortality ([@bb0065]). Macroalbuminuria is the common manifestation in progressive renal disease, and is viewed as a measurement of the severity and determinant for diabetic renal disease progression ([@bb0105]). In our present study, we only found a significant association between T2D_GRS and macroalbuminuria, but not microalbuminuria. Despite this, we also found that T2D_GRS was linearly related to Log-uACR. When using the un-weighted T2D_GRS, IS_GRS and GRS excluding those SNPs not in HWE (T2D_GRS/~25\ SNP~) as the IVs, we found a causal association between genetically determined T2D and increased uACR in the sensitivity analysis. Thus, our data also suggest potential causal relation between genetically determined T2D and albuminuria. Additional larger sample size MR studies or systemically functional investigations are needed to confirm this conjecture.

Several assumptions should be well met in performing a MR analysis ([@bb0150]). Firstly, the IV must not be correlated with confounders. In our study, the T2D_GRS was found to be associated with diabetes and diabetes-associated traits, but not with smoking, or drinking habits, physical activity, lipids or blood pressure, which are major risk factors for the renal disease. Nevertheless, the T2D_GRS was found to be associated with BMI and sex. To lessen the potential influence of pleiotropic effects of the IV, we examined the association of each SNP with other traditional factors related to decreased eGFR and increased uACR, such as BMI, SBP, DBP, TG and TG and performed sensitivity analysis by excluding those SNPs that associated with these metabolic traits. The IV estimated causal relationship remained significant. Secondly, the IV was strongly associated with exposure of interest. All variants used in this study have previously been shown to be strong associated with T2D in large meta-analysis of GWAS and could mostly be replicated in our present study. Thirdly, the IV related to outcome only through the exposure of interest. There should be no direct effect of genotype on disease or any other mediated effectors other than through the exposure of interest. Though this assumption is considered largely untestable, further adjustments of other potential confounders/mediators did change the results slightly in our analysis. We hypothesized that the association between genetically determined T2D with risk of decreased GFR is due to a direct consequence of being diabetes. We could not exclude the possibility that the associations of the genetic variants with T2D and with decreased eGFR are through completely different mechanisms. Pathway analysis in large meta-GWAS study or animal studies is warranted for verifying this assumption.

The strength of our study included the relative large sample size, well-defined community setting and the highly homogeneous population, the MR study design and a created T2D_GRS representing the combined effect of the established common genetic variants of T2D used as the IV. Several limitations should be acknowledged. Firstly, we used serum creatinine estimated GFR as marker of renal function, which thought to be usually accurate when GFR is below 60 ml/min and less accurate at normal or high GFR ([@bb0100]). The serum creatinine estimated GFR is widely used in the epidemiological studies due to good availability. Nevertheless, new methods such as the use of cystatin-C-based equations for estimating GFR would be considered in the future analysis. Secondly, the T2D_GRS only consisted of the validated common variants, which was considered to represent limited diabetes heritability so far. We were unable to assess the potential contribution of rare variants. Thirdly, though this study provided insights into the potentially causal effect of lifetime exposure of hyperglycemia, further investigations are needed to illustrate the precise mechanisms. Fourthly, because of the cross-sectional design, our findings may suggest the association is causal, further studies in prospective cohorts are needed to verify our findings. Finally, we created the T2D_GRS by using the common variants robustly associated with T2D in East Asians; it needs to be cautious to generalize the findings to other ethnicities or ethnic groups.

In conclusion, we found that a higher T2D_GRS was associated with higher risk of decreased eGFR. This analysis provides evidence for the biologically plausible causal relationship between genetically determined T2D and renal insufficient. Additional studies are needed to validate our findings and elucidate the mechanisms behind these findings.
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![Observed versus the IV estimated association of T2D with decreased eGFR and increased uACR. In the MR framework, T2D_GRS-T2D association is assumed to be independent of confounders. All the analyses were adjusted for age (years), sex, BMI (kg/m^2^), current smoking (yes or no), current drinking (yes or no), physical activity (mild, moderate or vigorous), hypertension (yes or no), total cholesterol (mmol/l), HDL-cholesterol (mmol/l), LDL-cholesterol (mmol/l) and triglycerides (mmol/l).](gr1){#f0005}

![Associations of IS_GRS and IR_GRS with decreased eGFR and increased uACR IS_GRS: insulin secretion associated genetic risk score; IR_GRS: insulin resistance associated genetic risk score. Data were presented as odds ratios (ORs) and 95% confidence intervals (CIs). *P* values were calculated from a multivariable logistic regression models after adjustment for age (years), sex, BMI (kg/m^2^), current smoking (yes or no), current drinking (yes or no), physical activity (mild, moderate or vigorous), hypertension (yes or no), total cholesterol (mmol/l), HDL-cholesterol (mmol/l), LDL-cholesterol (mmol/l) and triglycerides (mmol/l).](gr2){#f0010}

![The associations of different GRSs with log-eGFR and log-uACR. Data are presented as regression coefficient (β) and 95% confidence interval (CI). *P* values were calculated from multivariable linear regression models, after adjustment for age (years), sex, BMI (kg/m^2^), current smoking (yes or no), current drinking (yes or no), physical activity (mild, moderate or vigorous), hypertension (yes or no), total cholesterol (mmol/l), HDL-cholesterol (mmol/l), LDL-cholesterol (mmol/l) and triglycerides (mmol/l). T2D_GRS: type 2 diabetes genetic risk score; IR_GRS: insulin resistance associated genetic risk score; IS_GRS: insulin secretion associated genetic risks score; eGFR: estimated glomerular filtration rate; uACR: urinary albumin-to-creatinine ratio.](gr3){#f0015}

![Sensitivity analysis of the associations of genetically determined T2D with decreased eGFR and increased uACR. Data were presented as odds ratios (ORs) and 95% confidence intervals (CIs). *P* values were adjusted for age (years), sex, BMI (kg/m^2^), current smoking (yes or no), current drinking (yes or no), physical activity (mild, moderate or vigorous), hypertension (yes or no), total cholesterol (mmol/l), HDL-cholesterol (mmol/l), LDL-cholesterol (mmol/l) and triglycerides (mmol/l). T2D_GRS: type 2 diabetes genetic risk score; SD: standard deviation. T2D_GRS~/25\ SNP~ was calculated from the SNPs after excluding those were out of Hardy--Weinberg equilibrium (rs1801282, rs831571, rs6467136, rs864745, rs13266634, rs89654, rs17584499, rs111187 and rs1552224). T2D_GRS~/18\ SNP~ was calculated using the SNPs after excluding those may have potential pleiotropic effects (rs5215, rs4402960, rs1111875, rs243021, rs231362, rs10906115, rs3786897, rs9356744, rs17817449, rs6017317, rs17584499, rs2191349, rs1552224, rs7612463, rs13266634 and rs780094).](gr4){#f0020}

###### 

Characteristics of the participants according to quartiles of weighted T2D_GRS.

  *n*                          T2D_GRS        *P* for trend                                 
  ---------------------------- -------------- --------------- -------------- -------------- -----------
  Age, years                   63.2 ± 0.3     63.4 ± 0.3      63.3 ± 0.3     63.2 ± 0.3     0.91
  Male, *n*, %                 990 (34.3)     981 (34.1)      1056 (36.7)    1074 (37.4)    0.005
  Current smoker, *n* (%)      395 (14.6)     391 (14.5)      411 (15.1)     438 (16.1)     0.10
  Current drinker, *n* (%)     240 (8.9)      245 (9.1)       264 (9.8)      280 (10.3)     0.04
  BMI, kg/m^2^                 25.44 ± 0.07   24.36 ± 0.07    25.20 ± 0.07   25.11 ± 0.07   0.0004
  FPG, mmol/l                  5.78 ± 0.03    5.97 ± 0.03     6.09 ± 0.03    6.20 ± 0.03    \< 0.0001
  2 h PG, mmol/l               8.32 ± 0.07    8.82 ± 0.07     9.06 ± 0.07    9.40 ± 0.07    \< 0.0001
  Log-HOMA-IR                  0.47 ± 0.01    0.49 ± 0.01     0.50 ± 0.01    0.50 ± 0.01    0.02
  Log-HOMA-β, %                4.13 ± 0.01    4.06 ± 0.01     4.02 ± 0.01    3.97 ± 0.01    \< 0.0001
  Log-TG, mmol/l               0.29 ± 0.009   0.28 ± 0.009    0.28 ± 0.009   0.29 ± 0.009   0.98
  Total cholesterol, mmol/l    4.93 ± 0.02    4.94 ± 0.02     4.95 ± 0.02    4.96 ± 0.02    0.44
  SBP, mm Hg                   136.3 ± 0.4    136.9 ± 0.4     137.2 ± 0.4    137.2 ± 0.4    0.06
  DBP, mm Hg                   77.5 ± 0.2     77.2 ± 0.2      77.4 ± 0.2     76.9 ± 0.2     0.28
  Hypertension, *n* (%)        1680 (58.5)    1644 (57.2)     1655 (57.5)    1648 (57.4)    0.47
  Diabetes, *n* (%)            527 (18.3)     689 (24.0)      756 (26.3)     897 (31.2)     \< 0.0001
  Log-Creatinine, mg/dl        4.17 ± 0.003   4.18 ± 0.003    4.18 ± 0.003   4.19 ± 0.003   0.04
  Log-eGFR, ml/min/1.73 m^2^   4.77 ± 0.004   4.76 ± 0.004    4.75 ± 0.004   4.75 ± 0.004   0.04
  Log-uACR, mg/g               2.16 ± 0.02    2.19 ± 0.02     2.21 ± 0.02    2.23 ± 0.02    0.02
  Decreased eGFR, *n* (%)      231 (8.0)      257 (8.9)       264 (9.2)      283 (9.8)      0.02
  Increased uACR, *n* (%)      306 (10.6)     318 (11.1)      331 (11.5)     340 (11.8)     0.13

Data are age-, sex- and BMI-adjusted means ± standard errors (SE) for continuous variables or proportions for categorical variables. *P* for trend was calculated from the age-, sex- and BMI-adjusted linear regressions and Cochran--Armitage trend chi-square tests, respectively. T2D-GRS: type 2 diabetes genetic risk score; BMI: body mass index; FPG: fasting plasma glucose; 2 h PG: 2 h post-loading plasma glucose; HOMA-IR: homeostasis model assessment of insulin resistance; HOMA-β: homeostasis model assessment of β cell function; TG: triglyceride; uACR: urinary albumin-to-creatinine ratio; eGFR: estimated glomerular filtration rate. Decreased eGFR was defined as eGFR \< 90 ml/min/1.73 m^2^; increased uACR was defined as uACR ≥ 30 mg/g.

###### 

The associations of weighted T2D_GRS with decreased eGFR and increased uACR.

                                                            Model 1             Model 2                                 
  --------------------------------------------------------- ------------------- ------------------- ------------------- -------
  *Decreased eGFR, eGFR* *\<* *90* *ml/min/1.73* *m*^*2*^                                                               
  Continuous variable of T2D_GRS, per SD, 3.90                                                                          
                                                            1.12 (1.04, 1.20)   0.001               1.12 (1.04, 1.20)   0.002
  Categorical variable of T2D_GRS                                                                                       
  Q1                                                        1.00                0.004               1.00                0.005
  Q2                                                        1.16 (0.95, 1.41)   1.15 (0.94, 1.41)                       
  Q3                                                        1.19 (0.98, 1.44)   1.19 (0.97, 1.45)                       
  Q4                                                        1.33 (1.10, 1.61)   1.34 (1.10, 1.12)                       
  *Increased uACR, uACR* *≥* *30* *mg/g*                                                                                
  Continuous variable of T2D_GRS, per SD, 3.90                                                                          
                                                            1.05 (0.99, 1.12)   0.09                1.05 (0.98, 1.11)   0.16
  Categorical variable of T2D_GRS                                                                                       
  Q1                                                        1.00                0.04                1.00                0.09
  Q2                                                        1.06 (0.89, 1.25)   0.99 (0.83, 1.19)                       
  Q3                                                        1.12 (0.95, 1.33)   1.10 (0.92, 1.31)                       
  Q4                                                        1.17 (0.99, 1.38)   1.13 (0.95, 1.35)                       

Data are odds ratios (ORs) and 95% confidence intervals (CIs). *P* values were calculated from the multivariable-adjusted logistic regression models. Model 1, is adjusted for age, sex and BMI; Model 2, further adjusted for current smoking (yes or no), current drinking (yes or no), physical activity (mild, moderate or vigorous), hypertension (yes or no), total cholesterol (mmol/l), HDL-cholesterol (mmol/l), LDL-cholesterol (mmol/l) and triglycerides (mmol/l). T2D_GRS: type 2 diabetes genetic risks score; eGFR: estimated glomerular filtration rate; uACR: urinary albumin-to-creatinine ratio; SD: standard deviation; Q1: quartile 1; Q2: quartile 2; Q3: quartile 3; Q4: quartile 4.

[^1]: These authors contributed equally to this study.
